Posted 3/21/2024, 1:00:00 PM
Profluent Raises $44M to Scale AI for Gene Editing and Biomedicine
- Profluent secures $35M in additional funding, bringing total raised to $44M, to scale foundational AI models for biomedicine and tackle first vertical in gene editing
- Funding led by Spark Capital and includes participation from existing investors Insight Partners and Air Street Capital
- Profluent using AI to decode "language of life" and design novel proteins and gene editing systems; validated by peer-reviewed Nature Biotechnology paper
- New board members include Spark Capital's Fraser Kelton, former OpenAI head of product, and Nabeel Hyatt
- Funding to advance proprietary AI models, datasets, wet lab capabilities and CRISPR gene editing to design innovative, functional proteins